Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Sentinel lymph node biopsy (SLNB) has become a standard procedure for patients with breast cancer (BC) without clinically evident axillary metastasis. However, its role in cT3-4cN0 BC remains underexplored, leading to uncertainty regarding its safety.
Methods: This retrospective, multicenter observational study included patients with cT3-4cN0M0 BC who underwent radical surgery between 2006 and 2016. Patients were divided into an SLNB group, which included those who underwent SLNB exclusively and ALND after SLNB, and an ALND group, which included those who underwent ALND exclusively. Inverse probability treatment weighting was applied to balance the patient characteristics, with recurrence-free survival (RFS) as the primary endpoint.
Results: The study included 930 patients: 716 in the SLNB group and 214 in the ALND group. The ALND group had a higher proportion of patients diagnosed earlier, more T4 tumors, and more frequent use of neoadjuvant chemotherapy. During a median follow-up period of 89 months, 176 RFS events and 51 loco-regional recurrence events occurred. After adjusting for confounding factors, no significant difference was found in 10-year RFS between the groups (74.2% vs. 79.2%). Adjusted hazard ratios for RFS did not differ between the groups, even when stratified by tumor stage (cT3, cT4) or neoadjuvant chemotherapy. No significant differences were observed between the SLNB and ALND groups in loco-regional recurrence rate (LRR), with 10-year LRR rates of 93.1% and 90.8%, respectively.
Conclusions: SLNB was a safe axillary staging method for patients with cT3-4cN0M0 BC and does not impact RFS or LRR negatively when compared with ALND.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12282-025-01749-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility of the omission of axillary surgery in node-negative early breast cancer: a systematic review and meta-analysis.
Breast
August 2025
Aberdeen Royal Infirmary, Breast Unit, Foresterhill Road, Aberdeen, AB25 2ZN, UK. Electronic address:
Introduction: Recent and historical trials have suggested that the omission of axillary surgery is oncologically safe in node-negative early breast cancer. This meta-analysis investigates the feasibility of the omission of axillary surgery (SLNB or ALND) in terms of oncological outcomes and adjuvant treatment decisions.
Method: A systematic search of Medline, Embase and Cochrane Central was conducted.
Prognostic Outcomes by Axillary Approach in Lobular and Ductal Breast Cancer With Sentinel Node Macrometastases: A Retrospective Cohort Study.
Clin Breast Cancer
August 2025
IDIBELL Instituto de Investigación Biomédica de Bellvitge. Barcelona, Spain; Department of Oncology, Multidisciplinary Breast Cancer Unit,a Institut Català d'Oncología. Barcelona, Spain.
Purpose: To compare survival outcomes between patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma non-special type (NST) presenting with sentinel lymph node biopsy (SLNB)-detected macrometastases in early-stage breast cancer.
Materials And Methods: A retrospective cohort study was conducted including 364 cN0 breast cancer patients with SLNB-detected macrometastases who underwent surgical treatment between July 2011 and December 2023. Patients were categorized as NST (n = 250) or ILC (n = 108).
Management and Outcomes in Patients with Breast Cancer with 1-of-1 and 2-of-2 Positive Sentinel Nodes.
Ann Surg Oncol
August 2025
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Background: The ACOSOG-Z0011 and AMAROS trials showed that axillary lymph node dissection (ALND) provided no benefit for patients with 1-2 positive sentinel lymph nodes (+SLNs). There remains apprehension to omit ALND for patients in whom only 1-2 SLNs are retrieved and all are positive. This study evaluates current practices and pathological findings when ALND is pursued.
View Article and Find Full Text PDFClinical study of Tc-Rituximab combined with dyes double tracing for axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer.
Front Oncol
August 2025
Department of Breast Surgery, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
Background And Objective: Whether sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) for breast cancer is an alternative to axillary lymph node dissection (ALND) remains controversial. In this study, the results of SLNB performed with Tc-Rituximab combined with dyes were analyzed, and the application value of the double-tracing method of Tc-Rituximab combined with dyes in SLNB after breast cancer NAC was evaluated, the feasibility of SLNB after NAC and the clinical application of the novel tracer Tc-Rituximab and its value in internal mammary lymph node(IMLN) was discussed.
Methods: A retrospective analysis of 106 breast cancer patients who underwent post-NAC SLNB from August 2019 to August 2023 at Fujian Provincial Hospital, where SLNB was performed using Tc-Rituximab combined with dye imaging or dye imaging alone.
Additional Axillary Disease After Neoadjuvant Chemotherapy for Patients with Clinically Node-Negative but Sentinel Node-Positive Disease.
Ann Surg Oncol
August 2025
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Background: Axillary lymph node dissection (ALND) is associated with considerable risk of arm morbidity. This study aimed to identify risk factors for additional disease found at ALND in patients with a diagnosis of clinically node-negative (cN0) breast cancer who had sentinel lymph node (SLN) metastasis after neoadjuvant chemotherapy (NACT) as a help to identify patients for whom ALND may be safely omitted.
Methods: This retrospective national cohort study analyzed Danish patients with a diagnosis of cT1-3 breast cancer and cN0 disease from October 2016 to November 2022 but a positive SLN biopsy after NACT.